Why Vaxcyte, Inc. (PCVX) stock moved
Vaxcyte, Inc. (PCVX) shares tumbled 5.7% to $64.69 as of November 12, 2026, a significant decline from the prior close of $68.62. BestStocks flagged the session as a major change for PCVX. The move is tied to company news. Below, we break down what changed for PCVX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
PCVX tumbled 5.7% in its latest session, moving from $68.62 to $64.69.
What it means for Vaxcyte, Inc. investors
For Vaxcyte, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; PCVX moved +6.74% from its $55.17 open to a $58.89 close on 2026-08-06. Weighing against that: Sharp 5.7% decline — elevated risk; Vaxcyte announced that VAX-31 met all primary endpoints in its pivotal Phase III OPUS-1 trial, per defenseworld.net and an SEC 8-K filing today. Wall Street's consensus price target sits at $122.33, implying +89.1% upside from $64.69. BestStocks rates the overall signal quality low (55/100). With earnings roughly 103 days out, the next report is the most likely near-term test of the move.
PCVX price reaction
PCVX last traded at $64.69, down $3.93 (-5.73%) from the previous close of $68.62. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $59.97 and $70.65, and it currently sits about 44% of the way up that band.
Bullish and bearish analyst opinions on Vaxcyte, Inc. (PCVX)
The consensus analyst price target on Vaxcyte, Inc. (PCVX) is $122.33, 89.1% above the recent $64.69. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PCVX line up.
The bullish case
- Wall Street's consensus price target of $122.33 implies +89.1% upside from $64.69.
- The Street's most bullish target is $125.00 (+93.2%).
- Positive price momentum.
- PCVX moved +6.74% from its $55.17 open to a $58.89 close on 2026-08-06.
The bearish case
- Sharp 5.7% decline — elevated risk.
- Vaxcyte announced that VAX-31 met all primary endpoints in its pivotal Phase III OPUS-1 trial, per defenseworld.net and an SEC 8-K filing today.
- PCVX declined 4.35% intraday to $55.60 on below-average volume (0.47x expected).
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 12, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PCVX
In-depth PCVX event analyses
Frequently asked questions about PCVX
Why did Vaxcyte, Inc. (PCVX) stock move?
PCVX tumbled 5.7% to $64.69. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did PCVX stock fall?
PCVX lost 5.73% ($3.93) versus the prior close of $68.62, last trading at $64.69 on 0.6× average volume.
When is Vaxcyte, Inc.'s next earnings date?
PCVX's next earnings report is estimated for 2027-02-23 — about 103 days away.
What is the analyst price target for PCVX?
The consensus analyst price target for PCVX is $122.33, about 89.1% above the current $64.69. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks PCVX
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for PCVX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 12, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
